Neisewander J L, O'Dell L E, Redmond J C
Department of Psychology, Arizona State University, Tempe 85287-1104, USA.
Brain Res. 1995 Feb 13;671(2):201-12. doi: 10.1016/0006-8993(94)01317-b.
The purpose of this study was to examine whether blockade of either dopamine D1-like or D2-like receptors by selective antagonist administration into the nucleus accumbens (NAc) is sufficient to reverse cocaine-induced locomotion, and to develop a new technique that enables the population of receptors occupied by the antagonists to be quantified. Locomotor activity was assessed in rats that had received bilateral intra-accumbens injections of the D1-selective antagonist SCH-23390 (0-3.0 micrograms/0.5 microliters/side) or the D2/D3-selective antagonist sulpiride (0-1.0 micrograms/0.5 microliters/side), followed 15 min later by injections of saline or cocaine (15 mg/kg, i.p.). To assess receptor occupancy by the antagonists, 105 min prior to sacrifice the rats received intra-accumbens injections of the antagonist, followed 15 min later by an injection of the non-selective irreversible antagonist, N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline (EEDQ; 10 mg/kg, i.p.). Receptors were labeled with [3H]SCH-23390 or [3H]sulpiride in sections containing the NAc, and the autoradiograms allowed quantitation of receptors occupied (i.e. protected from EEDQ) by the antagonist given in vivo. Only a dose of 3 micrograms/side SCH-23390 reversed cocaine-induced locomotion, whereas a dose of 0.5 microgram/side did not alter cocaine-induced locomotion despite occupying the same amount of [3H]SCH-23390 binding sites in the NAc. Intermediate doses of 0.1 and 0.3 microgram/side sulpiride reversed cocaine-induced locomotion, and also occupied the greatest number of [3H]sulpiride binding sites in the NAc. The results suggest that blockade of D2-like, but not D1-like, receptors in the NAc is sufficient to reverse cocaine-induced locomotion, and also demonstrate the importance of quantifying receptors occupied by drugs administered intracranially.
本研究的目的是检验通过向伏隔核(NAc)注射选择性拮抗剂来阻断多巴胺D1样或D2样受体是否足以逆转可卡因诱导的运动,并开发一种新技术,能够对拮抗剂占据的受体数量进行量化。对接受双侧伏隔核注射D1选择性拮抗剂SCH-23390(0 - 3.0微克/0.5微升/侧)或D2/D3选择性拮抗剂舒必利(0 - 1.0微克/0.5微升/侧)的大鼠进行运动活性评估,15分钟后再注射生理盐水或可卡因(15毫克/千克,腹腔注射)。为了评估拮抗剂对受体的占据情况,在处死大鼠前105分钟,先向其伏隔核注射拮抗剂,15分钟后再注射非选择性不可逆拮抗剂N - 乙氧羰基 - 2 - 乙氧基 - 1,2 - 二氢喹啉(EEDQ;10毫克/千克,腹腔注射)。在含有伏隔核的切片中,用[3H]SCH - 23390或[3H]舒必利标记受体,放射自显影片可对体内给予的拮抗剂所占据(即免受EEDQ作用)的受体进行定量。仅3微克/侧的SCH - 23390剂量可逆转可卡因诱导的运动,而0.5微克/侧的剂量尽管占据了伏隔核中相同数量的[3H]SCH - 23390结合位点,但并未改变可卡因诱导的运动。0.1和0.3微克/侧的舒必利中间剂量可逆转可卡因诱导的运动,并且也占据了伏隔核中最多数量的[3H]舒必利结合位点。结果表明,阻断伏隔核中的D2样而非D1样受体足以逆转可卡因诱导的运动,同时也证明了对颅内给药所占据的受体进行定量的重要性。